BridgeBio Pharma (NASDAQ:BBIO – Free Report) had its target price increased by Bank of America from $42.00 to $45.00 in a ...

Massachusetts Financial Services Co. MA lifted its stake in BridgeBio Pharma, Inc. (NASDAQ:BBIO – Free Report) by 23.3% in ...

Oppenheimer analyst Trevor Allred maintained a Hold rating on BridgeBio Pharma (BBIO – Research Report) today. The company’s shares opened ...

Attruby (acoramidis), an orally-administered near-complete (≥90%) stabilizer of Transthyretin (TTR) for adults with ATTR-CM ...

BridgeBio Pharma Inc. ($BBIO) stock surged 28% on Monday morning, hitting highs last seen in mid-September, after the company ...

BridgeBio Pharma snagged FDA approval for its rival to Pfizer's heart disease treatment, Vyndaqel. BridgeBio stock catapulted ...

In a report released on November 23, Joshua Schimmer from Cantor Fitzgerald maintained a Buy rating on BridgeBio Pharma (BBIO – Research ...

On Friday, BridgeBio Pharma Inc (BBIO) stock saw a modest uptick, ending the day at $23.42 which represents a slight increase of $0.18 or 0.77% from the prior close of $23.24. The stock opened at $23.

(BBIO), the company announced that its innovative drug, Attruby (acoramidis), has received FDA approval for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM). This approval, granted by ...

We recently compiled a list of the 10 Worst Performing Biotech Stocks in 2024. In this article, we are going to take a look ...

On Friday, the FDA approved BridgeBio Pharma's Attruby (acoramidis), an orally-administered near-complete (≥90%) stabilizer ...

On Monday, BridgeBio Pharma, Inc. (NASDAQ:BBIO) presented initial outcomes from the ATTRibute-CM open-label extension (OLE) ...